Skip to main content

Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · IEX Real-Time Price · USD
3.05
+0.10 (3.39%)
After-hours:Sep 24, 2021 7:54 PM EDT
2.95
-0.05 (-1.67%)
At close: Sep 24, 4:00 PM
Market Cap38.52M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out13.06M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume172,040
Open2.89
Previous Close3.00
Day's Range2.88 - 3.04
52-Week Range2.65 - 4.19
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About KTTA

Pasithea Therapeutics is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. As of March 26, 2021, the Company had not commenced core operations. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. Our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing n...

IndustryBiotechnology
IPO DateSep 15, 2021
CEODr. Tiago Reis Marques
Employees1
Stock ExchangeNASDAQ
Ticker SymbolKTTA
Full Company Profile

News

Pasithea Therapeutics Corp. Announces Closing of $24.0 Million Initial Public Offering

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company...

1 week ago - GlobeNewswire

Pasithea Therapeutics Corp. Announces Pricing of Upsized $24.0 Million Initial Public Offering

Pasithea Therapeutics Corp. ("Pasithea" or the "Company"), a biotechnology company focused on the...

1 week ago - GlobeNewswire

Pasithea Therapeutics IPO Registration Document (S-1)

Pasithea Therapeutics Corp. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC